The HTA Council recommends the multi-dose vial preparation of pneumococcal conjugate vaccines (PCV) indicated for the following minimum serotypes: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Both PCV10 and PCV13 which are currently authorized by the Philippine FDA on the publication date of this evidence summary represent good value for money, with the potential of reducing pneumococcal diseases in the country. To ensure equity, affordability, and universal vaccine coverage which can only be ensured by obtaining lower vaccine prices, a competitive tendering process is important. (See below for more details)